Novozymes Biopharma has introduced a new brand for its recombinant human albumin (rAlbumin) portfolio, bringing both of its rAlbumin products under its established Recombumin brand. Albucult will be renamed Recombumin Alpha, and Recombumin will now be known as Recombumin Prime. The products, as well as the product codes, will remain the same, but there will be changes reflected on both marketing materials and product labeling.
 
“Novozymes is delighted to announce that it is synchronizing the branding of its rAlbumin products under the Recombumin family name to enhance the clarity of the company’s product offering, while still providing customers with the same superior solutions,” said Dermot Pearson, marketing director, Novozymes Biopharma. “Since we launched our rAlbumins the portfolio has gone from strength-to-strength helping Novozymes to become one of the fastest growing companies in the industry.”